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Abstract
Thromboxane synthase (TXSA), an enzyme of the arachidonic acid metabolism, is upregulated in human glial tu-
mors and is involved in glioma progression. Here, we analyzed the in vitro and in vivo effects of pharmacological
inhibition of TXSA activity on human glioblastoma cells. Furegrelate, a specific inhibitor of TXSA, significantly in-
hibited tumor growth in an orthotopic glioblastoma model by inducing proapoptotic, antiproliferative, and anti-
angiogenic effects. Inhibition of TXSA induced a proapoptotic disposition of glioma cells and increased the sensitivity
to the chemotherapeutic agent 1,3-bis(2-chloroethyl)-1-nitrosourea, significantly prolonging the survival time of
intracerebral glioma-bearing mice. Our data demonstrate that the targeted inhibition of TXSA activity improves the
efficiency of conventional alkylation chemotherapy in vivo. Our study supports the role of TXSA activity for the
progression of malignant glioma and the potential utility of its therapeutic modulation for glioma treatment.
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Introduction
Despite recent advances in neurosurgical techniques and the introduc-
tion of radiotherapy plus concomitant and adjuvant temozolomide,
the prognosis of patients with malignant glioma remains grim [1,2].
The diffusely infiltrative nature of gliomas limits complete surgical re-
moval and is one of the major factors responsible for the almost in-
evitable tumor recurrence. No anti-invasive therapy is available yet,
and current conventional chemotherapeutic approaches have shown
only modest efficiency. Toxicity, drug delivery, and the development
of drug resistance are the main problems associated with standard che-
motherapeutic regimens for malignant brain tumors [3]. Optimization
of drug delivery and the development of combinations of compounds
that target specific pathobiologic programs of glioma cells are manda-
tory to overcome these problems [4,5].
Recent data indicated that thromboxane synthase (TXSA), an en-
zyme of the arachidonic acid pathway, promotes tumor growth and is
involved in tumor invasion and metastasis in a variety of cancer types
[6–9]. Thromboxane synthase mediates the conversion of the prosta-
glandin endoperoxide into thromboxane A2 (TXA-2), which is one
of the downstream metabolites of cyclooxygenase. Originally, TXA-2
was described for its physiological function as a promoter of platelet
aggregation, vasoconstriction, and bronchoconstriction [10]. How-
ever, TXSA is highly overexpressed in human gliomas, and expres-
sion levels correlate with the grade of malignancy [11,12]. TXSA is
involved in the regulation of the migratory phenotype of human
glioma cells and provides a potential target for an anti-invasive and
proapoptotic strategy [12–14]. The expression of TXSA is coregu-
lated by the tumor suppressor gene p53 and the proto-oncogenic
factor ets-1 in an antagonistic fashion [7]. Thus, the development
of an apoptosis-resistant and highly invasive glioma phenotype may
be due to the loss of p53-mediated negative control over the ets-1–
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dependent transcription of the TXSA gene. TXSA-specific inhibitors
have been shown to block the migration of human glioma cells in vitro
and render migration arrested human glioma cell lines highly suscep-
tive to apoptosis-inducing agents [14] and γ-radiation [15]. Therefore,
inhibition of TXSA activity is an attractive target for the treatment of
human glioblastoma and has the potential to increase the efficiency of
conventional chemotherapeutic strategies.
In this study, we investigated the effects of the specific TXSA in-
hibitor furegrelate on glioma cell sensitivity to the chemotherapeutic
agent 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and its therapeu-
tic effects in an intracerebral glioblastoma model. Our results demon-
strate that the pharmacological inhibition of TXSA activity inhibits
glioblastoma growth by proapoptotic, antiproliferative, and antiangio-
genic effects and significantly enhances the survival promoting effects
of a systemic BCNU therapy.
Materials and Methods
Cell Culture
The human glioblastoma cell line U87 (American Type Culture
Collection, Manassas, VA) was cultured in α-minimum essential me-
dium (GIBCO BRL, Grand Island, NY) supplemented with 2 mM
L-glutamine, 2 mM sodium pyruvate, 100 U/ml penicillin, 100 μg/ml
streptomycin, 0.25 μg/ml fungizone, and 10% fetal bovine serum
(GIBCO). Cells were maintained in T-75 tissue culture flasks in
5% CO2/95% air at 37°C in a humidified incubator and routinely
passaged at subconfluency. For the intracranial implantation experi-
ments, U87 cells were dispersed with a 0.05% solution of trypsin/
EDTA (GIBCO), washed with phosphate-buffered saline (PBS), and
adjusted to a final concentration of 5 × 104 cells/10 μl in PBS. 1,3-Bis
(2-chloroethyl)-1-nitrosourea (Bristol,Munich,Germany) and the chem-
ically stable and water-soluble specific inhibitor of TXSA, furegrelate
(sodium 5-[3′-pyridinylmethyl] benzofuran-2-carboxylic acid; Biomol,
Hamburg, PA) were prepared and stored according to the manufac-
turer’s instructions.
Cell Growth Assay
The human glioblastoma cell line U87 was seeded at 2000 cells
per well in a 96-well plate and incubated for 30 minutes on ice to
allow attachment [11]. The specific TXSA inhibitor furegrelate was
added daily, and replicate wells were fixed daily in 1% glutaraldehyde
(Serva Electrophoresis GmbH, Heidelberg, Germany). Cells were
stained with 50 μl of crystal violet for 1 hour. Cell number was de-
termined in triplicate by absorbance measurements at 540 nm of
destained nuclei after 10% SDS treatment.
Colony Formation Assay
The human glioblastoma cell line U87 was seeded in 10-cm culture
dishes and maintained until subconfluence. The cultures were treated
with the TXSA inhibitor furegrelate and BCNU at doses indicated
in the figures. After 24 hours of incubation, cells were trypsinized,
washed in PBS, and counted. A single-cell suspension was plated in
minimum essential medium containing 10% fetal calf serum into six-
well plates at a density of 5 × 105 cells per well. The cultures were main-
tained for twoweeks, and then the cells were fixed in 1% glutaraldehyde
and stained using crystal violet. The number of colonies was counted,
and the surviving fraction was calculated as the percentage of colonies
of the untreated control.
Cell Death Assay
Apoptosis and necrotic cell death were analyzed using the cell death
detection ELISAPlus kit (Roche, Mannheim, Germany) as previously
described [14]. In this assay, the intracellular enrichment of mono-
nucleosomes and oligonucleosomes, which occur after induction of
endogenous endonucleases, is because, in apoptosis, DNA degradation
occurs several hours before plasma membrane breakdown. In contrast,
necrotic cell death results in the early release of fragmented DNA into
the culture supernatant. Briefly, 2 × 104 U87 cells were seeded into a
96-well plate and allowed to adhere for 4 hours before treatment. Cells
were washed, and the medium was replaced with serum-free medium,
after which furegrelate, BCNU, or combinations thereof were added at
various concentrations. After 48 hours, the supernatant was aspirated,
cells were lysed, and apoptosis as well as necrosis was determined fol-
lowing the manufacturer’s instructions. A specific enrichment factor of
mononucleosomes and oligonucleosomes released into the cytoplasm
was calculated by the absorbance of the treated sample divided by the
absorbance of the corresponding untreated control. Values were as-
sessed in triplicate and expressed as mean ± SD.
In Vivo Studies
All animal work was carried out in accordance with federal, local and
institutional guidelines. Orthotopic human glioblastoma xenografts
were established in 4- to 6-week-old male Swiss nude mice (Taconic,
Germantown, NY) as previously described [16]. Mice were anesthe-
tized (100 mg/kg ketamine and 5 mg/kg xylazine) and received a
stereotactically guided injection of 5 × 104 human U87 glioma cells
into the left basal ganglia (2 mm lateral and 1 mm anterior to bregma,
at a 3-mm depth from the skull surface) after a small craniectomy.
Eight days after tumor cell injection, 5 to 10 mice were randomized
for the treatment and control groups. Each experiment was performed
in duplicate. In the first experiment (end point study), Alzet osmotic
minipumps (Durect Corporation, Cupertino, CA) designed to deliver
0.25 μl/h for 4 weeks were used for intratumoral drug delivery as
previously described [16]. The pumps were filled with furegrelate
to deliver 0.5 or 2 mg/kg per day, or PBS for the control animals,
and were connected to a brain infusion cannula through a catheter
tube according to the manufacturer’s instructions (Brain Infusion
Kit, Durect). To establish a constant flow before implantation, the
filled pumps were incubated overnight in sterile PBS at 37°C. Eight
days after injection of U87 glioma cells, the pump reservoirs were
placed subcutaneously in the left flank of the anesthetized mice. The
brain infusion cannula was tunneled subcutaneously and fixed to the
skull with surgical glue at the initial tumor cell injection site resulting
in an intratumoral localization of the cannula tip (∼2-2.5 mm in
depth). Closure of the incisions was performed by suture. All groups
were killed by CO2 inhalation 21 days after treatment was initiated.
Brains were removed, embedded in OCT, and stored at −80°C until
further processed for histologic analysis. In the second experiment (sur-
vival study), the effects of the local microinfusion of furegrelate alone
and in combination with systemic administration of BCNU on the
survival of U87 human glioblastoma-bearing nude mice were assessed.
Implantation of osmotic minipumps 8 days after tumor cell injections
was performed as described previously. Pumps were filled either with
PBS or with furegrelate to deliver 2 mg/kg per day in PBS solution.
Systemic BCNU treatment [17] was performed by single daily intra-
peritoneal injections (i.p.; 15 mg/kg per day) for 5 days starting day 10
after tumor cell injection. In this experiment, animals were killed at the
onset of neurologic signs or any type of distress.
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Immunohistochemical Analyses
Frozen brains were cut in serial 10-μm sections and stained with he-
matoxylin and eosin for histologic evaluation. Tumor volumes were cal-
culated by the ellipsoid formula [18]. Immunohistochemistrywas carried
out using standard techniques with the Vectastain Elite ABC kit (Vector
Laboratories, Burlingame, CA). Primary antibodies included anticleaved
caspase 3 (1:100; Cell Signaling Technology, Beverly, MA) for the detec-
tion of apoptosis, anti-CD31 (1:100; BD Biosciences Pharmingen, San
Jose, CA) for blood vessels and anti-Ki67 nuclear antigen (1:100;DAKO,
Carpinteria, CA) for detection of cell proliferation. Sections were counter-
stained with hematoxylin, and negative control slides were obtained by
omitting the primary antibody. The apoptosis and proliferation index
were quantified by counting the number of positively stained cells of
100 nuclei in five randomly chosen high-power fields. The intratumoral
microvessel density was assessed as described by Leon et al. [19]. For the
identification of hemosiderin deposits as a sign for microhemorrhages,
we used the Prussion-Blue reaction with a neutral red counterstain.
Statistics
All values were calculated as mean ± SD or expressed as percentage
of control ± SD. Significant differences between tumor volumes, mi-
crovessel density, proliferation, and apoptosis index were determined
using the Mann-Whitney rank sum test (MW test) or the unpaired
t test. Kaplan-Meier survival curves were statistically analyzed using
the Cox regression analysis.
Results
Proapoptotic Synergism of the Specific TXSA Inhibitor
Furegrelate with BCNU on Human U87 Glioblastoma Cells
We have previously shown that human glioblastoma including the
human glioblastoma cell line U87 expresses both TXSA and the
thromboxane receptor [12,15]. Treatment of U87 glioma cells with
furegrelate leads to migration arrest and induction of apoptosis. Fur-
ther, pretreatment with furegrelate sensitized U87 cells to radiation-
induced cell death [15]. To test whether TXSA inhibitors inhibit the
growth of U87 cells, in vitro growth curve experiments using increas-
ing concentrations of furegrelate were performed. This demonstrated
that single doses of furegrelate as low as 0.1 mg/ml added to the cul-
ture medium inhibited cell growth (Figure 1A). Confirming our pre-
vious findings, furegrelate resulted in a significant histone-complexed
DNA fragmentation of U87 cells in an apoptosis assay 48 hours after
Figure 1. In vitro effects of the specific TXSA inhibitor furegrelate on the human U87 glioblastoma cell line. (A) Increasing concentrations
of furegrelate reduced the cell growth of U87. (B) Cotreatment of U87 with furegrelate and BCNU leads to a robust synergistic apoptotic
effect in vitro indicating a sensitizing effect of furegrelate. Tumor cells were incubated with indicated concentrations and combinations
of furegrelate and/or BCNU for 48 hours. DNA fragmentation was determined in cellular lysates (bars) and culture supernatant (o). No
significant amounts of DNA fragments could be detected in the cell culture supernatant indicating that the effects were a consequence
of apoptotic cell death and not of cellular necrosis. All values shown are mean ± SD. (C) Cotreatment with furegrelate and BCNU lead to
a synergistic decrease in the surviving fraction of U87 tumor cells as determined by a colony formation assay. Values were calculated as
mean ± SD of triplicate determinations.
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treatment. BCNU treatment at concentrations of 50 and 100 μg/ml
also induced apoptosis. However, cotreatment of 0.5 mg/ml furegrelate
and increasing doses of BCNU demonstrated significantly increased
intracellular DNA fragmentation over the single-agent treatments
(Figure 1B). To demonstrate a synergistic effect of furegrelate and
BCNU, a colony formation assay was used. This showed that increas-
ing concentrations of furegrelate and BCNU lead to a dose-dependent
decrease of the clonogenic surviving fraction of U87 cells (Figure 1C).
The TXSA Inhibitor Furegrelate Inhibits Intracerebral
Glioblastoma Growth by Proapoptotic, Antiproliferative,
and Antiangiogenic Effects In Vivo
We next determined the in vivo effects of furegrelate on the intra-
cerebral growth of established human U87 glioblastoma xenografts.
To gain insight into the mechanism of action of TXSA inhibition, all
animals were killed 21 days after initiation of treatment, and the
brains were processed for immunohistochemical analyses. Therapeu-
tic local intracerebral microinfusions were established by implan-
tation of osmotic minipumps at the tumor site 8 days after glioma
cell injection. The direct intracerebral release of a daily total dose of
2 mg/kg of the specific TXSA inhibitor furegrelate resulted in a sig-
nificant tumor growth inhibition when compared with the control
group receiving intralesional infusions of PBS (73.1%, P < .05; Fig-
ures 2A and 3, A and A′). This antitumor effect was mediated by a
significant increase in the apoptosis index (2.9-fold, P < .005; Fig-
ures 2B and 3, B and B′) and a significant reduction of the intra-
tumoral microvessel density (30.4%, P < .05; Figures 2C and 3, C
and C ′) and tumor cell proliferation (24.1%, P < .01; Figures 2D
and 3, D and D′). These proapoptotic, antiangiogenic, and antipro-
liferative effects of TXSA inhibition were dose-dependent because no
significant antitumor effects were observed at 0.5 mg/kg per day of
furegrelate (Figure 2, A–D). However, at this dose, the intratumoral
blood vessel density was still slightly reduced by 14% (P < .05;
Figure 2C ) when compared with the control group, indicating activ-
ity of furegrelate on inhibition of TXSA, although not sufficient to
elicit a significant antitumor effect. Local intracerebral delivery of
furegrelate seemed safe because animals from all groups did not show
any significant weight loss or signs of adverse effects due to the treat-
ment. Histologic screening of the brain sections did not reveal any
signs for intratumoral hemosiderin deposits, indicating that the anti-
angiogenic effects did not induce any intracerebral hemorrhage. Only
in one control and in one furegrelate-treated animal that minor he-
mosiderin deposits were identified at distance from the tumor and
the cannula site of the pump. All pump reservoirs displayed a de-
creased volume at the end of the experiments, indicating that fureg-
relate was delivered as expected.
Local Therapy with Furegrelate in Combination with
Systemic BCNU Therapy Improves Survival in an
Intracerebral Glioblastoma Model
We next asked whether the inhibition of TXSA activity by local in-
tracerebral microinfusion of furegrelate results in an increased survival
time of nude mice with established orthotopic human U87 glioblas-
toma xenografts. Furthermore, we were interested if the proapoptotic
Figure 2. The local intracerebral infusion (i.c.) of 2 mg/kg per day of furegrelate is more effective than 0.5 mg/kg per day on established
human U87 glioblastoma xenografts in nude mice. (A) The local delivery of 2 mg/kg per day of furegrelate reduced the tumor growth of
U87 human glioblastoma xenografts by 73.1% (*P < .05) as assessed by histologic volume measurement 21 days after treatment was
initiated. Treatment with 2 mg/kg per day of furegrelate induced (B) a significantly increased apoptosis index (2.9-fold, *P < .005). Fur-
thermore, treated tumors displayed (C) a significantly reduced intratumoral microvessel density (30.4%, *P < .05) and (D) a significant
reduction of tumor cell proliferation (24.1%, *P < .01).
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disposition due to inhibition of TXSA activity would enhance the ther-
apeutic benefits of systemically administered BCNU chemotherapy.
Osmotic minipumps were implanted at the tumor site 8 days after tu-
mor cell injection. The pump reservoirs were filled either with PBS
for the control group or with furegrelate at a total daily dosage of
2 mg/kg. BCNU-treated animals received a single daily i.p. injection
of 15 mg/kg BCNU for 5 days starting at day 10 after tumor cell in-
jection. The antitumor effects of furegrelate at 2 mg/kg per day did not
translate into a significant survival benefit compared with PBS-treated
animals (P = .211; Figure 4). Whereas most animals in the control
group had died by day 30, three animals of the furegrelate-treated group
lived longer than day 36, which was the maximum duration of fureg-
relate delivery by the osmotic minipumps. The dosage of 15 mg/kg per
day of BCNU significantly increased the mean survival time by 9 days
compared with the control group (P < .0001). However, the pharmaco-
logical inhibition of TXSA by furegrelate (2 mg/kg per day) followed by
a systemic BCNU therapy significantly prolonged the survival time (P <
.0001; Figure 4). The median survival time was increased by 16 days
compared with the controls in this highly aggressive orthotopic glioblas-
toma model. We observed no clinical apparent adverse effects and no
significant weight loss in the treatment groups.
Discussion
The current standard of care for patients with malignant glioma consists
of surgical tumor resection followed by a combination of radiotherapy
Figure 3. Histologic examination after 21 days of treatment with the local intracerebral microinfusion of 2 mg/kg per day of furegrelate.
Representative examples of U87-derived tumors grown in the brain of animals that received PBS i.c. (A–D) or 2 mg/kg per day of furegrelate
locally (A′–D′). (A, A′) Frozen sections stained with hematoxylin and eosin. (B, B′) Apoptotic tumor cells as assessed by immunoreactivity for
cleaved caspase 3. (C, C′) Microvessel density as assessed by immunoreactivity for the endothelial cell marker CD31. (D, D′) Proliferating
tumor cells as assessed by immunoreactivity for Ki67. Scale bar, 100 μm.
Figure 4. Kaplan-Meier survival curve of human U87 glioblastoma-bearing nude mice. The local intracerebral microinfusion (i.c.) of fureg-
relate at 2 mg/kg per day from day 8 to 36 in combination with a BCNU chemotherapy administered i.p. at 15 mg/kg per day from day 10 to
14 further increased the survival benefits of BCNU therapy (P < .0001).
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with temozolomide [1]. Despite a statistically relevant benefit in overall
survival for patients with a newly diagnosed glioblastoma, this improve-
ment remains modest from a clinical viewpoint. Tumor recurrence is
still inevitable, and further meaningful therapeutic options are still un-
resolved. BCNU has been used as an adjuvant chemotherapeutic drug
in the treatment of malignant glioma for decades [20]. Recently, the
implantation of biodegradable BCNU-releasing wafers after surgical re-
moval of a tumor mass has been demonstrated to offer a survival ben-
efit to patients with primary and recurrent glioblastoma [21,22]. It is
the first clinically approved local-regional chemotherapy for malignant
glioma patients. Nevertheless, the development of combinations of
compounds that target specific pathobiologic programs of glioma cells
and the potential to enhance the effectiveness of current chemothera-
peutic strategies are clearly needed [5,23].
The overexpression of TXSA is associatedwith tumor progression and
metastasis in a variety of cancer types [8,12,24–26]. Cancer-promoting
effects of TXSA activity seem to include the augmentation of tumor an-
giogenesis and tumor cell invasion [6,12,25,27]. However, the in vivo
effects of TXSA inhibition have been hardly investigated in orthotopic
cancer models. In this study, we demonstrated that the pharmacological
inhibition of TXSA activity by furegrelate inhibits intracerebral glioblas-
toma growth. This tumor inhibition was mediated by proapoptotic,
antiproliferative, and antiangiogenic effects. Our findings are supported
by a previous study demonstrating that the experimental overexpression
of TXSA promoted tumor growth in an adenocarcinoma mouse model
by enhancing angiogenesis [6]. Intratumoral endothelial cells of malig-
nant gliomas are known to express high levels of TXSA [12,28]. TXA-2,
the active metabolite of TXSA activity, is involved in the angiogenic
process by stimulating endothelial cell migration and vascular smooth
muscle cell proliferation [10,27,28]. Furthermore, TXA-2 synthesis in
endothelial cells is stimulated by fibroblast growth factor-2 and vascu-
lar endothelial growth factor, which are highly expressed in malignant
glioma and are essential key players of glioma progression [27,29].
Our data confirmed the relevance of TXSA activity for glioma angiogen-
esis in vivo. Pharmacological inhibition of its activity led to a significant
reduction of intratumoral microvessel density.We observed an increased
glioma cell apoptosis and a reduced tumor proliferation rate, which may
be in part due to the antiangiogenic effects of TXSA inhibition. How-
ever, our in vitro data demonstrated that furegrelate exerts potent direct
antitumor effects by impairing cell growth, inducing apoptosis, and
decreasing clonogenic cell survival of human U87 glioblastoma cells.
TXSA overexpression in glioma cells was initially identified in a
human glioma cell line selected for a highly migratory phenotype by
using differential messenger RNA expression analysis [13]. We have
previously demonstrated that the level of TXSA activity correlates with
the in vitro migration rate of a variety of human glioma cell lines and
that pharmacological inhibition of this enzyme blocks tumor cell mo-
tility [12]. Remarkably, this increased the in vitro sensitivity to apop-
tosis induced by etoposide, camptothecin, or BCNU [14]. A similar
sensitizing effect of TXSA inhibition was recently shown for bladder
cancer cell lines in response to cisplatin and paclitaxel [9], but the rel-
evance of the increased tumor cell chemosensitivity has never been in-
vestigated in vivo. Here, we expanded these findings and demonstrated
that furegrelate induced a proapoptotic disposition of human glioblas-
toma cells and increased the sensitivity to the chemotherapeutic drug
BCNU in vivo, which significantly prolonged the survival time of in-
tracerebral glioma-bearing mice.
We have previously shown that inhibition of TXSA by furegrelate
also sensitized experimental glioma to radiation therapy [15].γ-Radiation
alone led to an induction of endogenous thromboxane synthesis, im-
plicating TXSA as a survival factor. Metabolites of the arachidonic acid
pathway influence a multitude of cellular properties [30]. Inhibition of
TXSA activity may lead to an accumulation of further upstreammetabo-
lites possibly activating alternative pathways, which may be responsible
for the failure of pharmacological TXSA inhibition alone to prolong
the survival of intracerebral glioma-bearing mice despite its potent anti-
tumor effects in our end point study.
It seems reasonable to speculate that therapeutic inhibition of TXSA
activity has the clinical potential to inhibit the invasive phenotype of
glioma cells. Current experimental glioblastoma models do not reflect
the full invasive phenotype of human tumors. However, recent findings
indicated that intracerebral xenografts of glioblastoma-derived stem cell
lines display a highly invasive tumor growth and may be ideal models
to evaluate anti-invasive strategies in future studies [31]. Among the
compounds tested for modulating the metabolic pathway of arachi-
donic acid, furegrelate displays the most potent antitumor effects on
human glioma cells [11,32]. TXSA inhibitors have undergone clinical
testing for modulating platelet aggregation or vasoconstriction in a va-
riety of diseases [10]. Human clinical studies with furegrelate indicated
that it is a well-tolerated effective inhibitor of thromboxane synthesis
when administered chronically [33,34]. Despite its known modulation
of platelet aggregation and its antiangiogenic effects, we did not ob-
serve any intracerebral hemorrhage in our study. This is the first study
demonstrating that the pharmacological inhibition of TXSA sensitizes
glioma cells to alkylation chemotherapy in vivo. Our data warrant fur-
ther investigation of its value as an adjuvant therapeutic strategy for gli-
oma treatment. Taken together, targeted inhibition of TXSA activity
may have the potential to improve the efficiency of conventional che-
motherapy and radiotherapy.
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